Truist Financial Reaffirms Their Hold Rating on Pediatrix Medical Group (MD)
In a report released today, David S Macdonald from Truist Financial maintained a Hold rating on Pediatrix Medical Group. The company’s shares closed yesterday at $21.08.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, S Macdonald is a 5-star analyst with an average return of 10.1% and a 58.28% success rate. S Macdonald covers the Healthcare sector, focusing on stocks such as DaVita, HCA Healthcare, and Humana.
In addition to Truist Financial, Pediatrix Medical Group also received a Hold from TR | OpenAI – 4o’s Rosa Clinessa in a report issued yesterday. However, today, TR | OpenAI – 4o upgraded Pediatrix Medical Group (NYSE: MD) to a Buy.
The company has a one-year high of $21.24 and a one-year low of $11.84. Currently, Pediatrix Medical Group has an average volume of 836.9K.
Read More on MD:
Disclaimer & DisclosureReport an Issue
- Pediatrix Medical Group: Strong Financial Performance and Strategic Improvements Justify Buy Rating
- Pediatrix Medical reports Q3 adjusted EPS 67c, consensus 47c
- Pediatrix Medical raises FY25 adjusted EBITDA view to $270M-$290M
- MD Earnings this Week: How Will it Perform?
- Pediatrix Medical price target raised to $17 from $16 at Truist
